Pro-apoptotic Targeting Peptide
Adipotide is a fat-loss peptide designed to target the blood supply feeding fat cells, causing them to shrink without directly affecting surrounding tissue. Studies reported an 11% reduction in body weight and a 27% reduction in abdominal circumference within 28 days without calorie restriction. It works through a different mechanism from appetite-based compounds by targeting the vasculature of fat depots.
Product
Research shows
Practical product identifiers and format details for professional review.
Content
30 mg
Format
Injectable
Composition
10 mg/ml per ml
Adipotide consists of two functional domains: a targeting motif that binds prohibitin on the surface of adipose-vasculature endothelial cells and a pro-apoptotic sequence derived from the D(KLAKLAK)2 antimicrobial peptide. Once bound to the adipose blood-vessel surface, the pro-apoptotic domain disrupts mitochondrial membranes in endothelial cells, triggering apoptosis and vascular regression specifically in white adipose depots. Studies reported an 11% reduction in body weight and a 27% reduction in abdominal circumference over four weeks.
Based on published research and preclinical data. All benefits are documented under research-grade conditions.
Adipotide is the only fat-loss compound that targets the blood supply to fat cells rather than the fat cells themselves. By triggering apoptosis in the blood vessels feeding white adipose tissue, it causes fat cells to lose their nutrient supply, triggering shrinkage and cell death from the outside in.
Studies reported an 11% reduction in body weight and a 27% reduction in abdominal circumference within 28 days while examining Adipotide's vascular-targeting mechanism. Caloric intake was not controlled in the principal study, so the finding should be interpreted within that research context.
The prohibitin receptor targeted by Adipotide is expressed in both visceral and subcutaneous white adipose tissue, making it effective against both fat depot types: unlike some agents that preferentially affect one or the other.
Adipotide's mechanism is entirely peripheral and does not require engaging the central nervous system, GLP-1 receptors, or hormone pathways. This makes it potentially useful for individuals where CNS-acting appetite agents are contraindicated or ineffective.
The prohibitin receptor that Adipotide targets is predominantly expressed on adipose vasculature endothelial cells. Surrounding muscle, organ, and other tissue vasculature expresses significantly lower levels, conferring a degree of selectivity that limits off-target effects.
Adipotide represents a new class of 'vascular-targeting peptides' for metabolic disease. Its development by Wadih Arap and Renata Pasqualini at MD Anderson Cancer Center reflects its roots in tumour vasculature research: the same targeting strategy used in some anticancer compounds.
Explore selected publications on Adipotide, with links to the original sources.
5 publications from the research library.
Evidence type
Publication and key finding
Source
Evidence type
Published research
Foundational adipose-vasculature targeting study
Publication and key finding
Targeting the blood vessels that support white adipose tissue caused selective vascular ablation and substantial fat loss in obese mice, establishing the core adipotide research strategy.
Nature medicine
Evidence type
Preclinical study
Adipotide target-mechanism evidence
Publication and key finding
Animal and cellular experiments identified endothelial prohibitin as a bidirectional transporter involved in long-chain fatty-acid movement into white and brown adipose tissue.
Diabetes
Evidence type
Preclinical study
Adipotide target-pathway evidence
Publication and key finding
The interaction between prohibitin and annexin A2 regulated fatty-acid transport across adipose vascular endothelium, clarifying a pathway used in adipose-targeting research.
JCI insight
Evidence type
Foundational research
Background on the vascular-targeting platform
Publication and key finding
In-vivo phage display in people identified organ-specific vascular receptor signatures, providing the translational basis for selectively delivering compounds to defined tissues.
Nature medicine
Evidence type
Review
Adipotide mechanism or target context
Publication and key finding
Recent meta-analyses of new anti-obesity drugs and their weight-loss efficacy have shown that the overall placebo-subtracted weight reduction (%) for at least 12 months ranged from 2.9 to 6.8% for the following drugs: phentermine/topiramate (6.8%), liraglutide (5.4%), naltrexone/bupropion (4.0%), orlistat (2.9%), and lorcaserin (3.1%).
Current obesity reports
Labbieux pens are designed for 30 to 31 administrations of 10 clicks. With daily use, this corresponds to approximately one month. We recommend starting with 5 clicks and building up to 10 clicks per administration. More sensitive people may use fewer clicks.
Before using our pens, consult the manual.
Adipotide carries the most significant safety caution of any product in this catalogue. Preclinical trials observed renal toxicity, including increased creatinine and reduced GFR, attributed to the proximity of renal vasculature to adipose depots around the kidneys. Renal-function monitoring is essential throughout use. The pro-apoptotic domain is inherently toxic to cells it reaches; its selectivity depends on the targeting domain, and any loss of targeting specificity could produce off-target vascular damage. Adipotide is therefore strictly an advanced research compound requiring careful monitoring and is not appropriate for unsupervised self-administration. Strict adherence to dosing protocols and renal-function monitoring at baseline and during use is mandatory.
This public COA documents one selected production batch and is updated annually. It is not the COA for our latest available batch. Every batch has its own documentation, and partners can request the latest batch COA from our team.
Other products from the same range
